KITOV PHARMA LT/S (NASDAQ:KTOV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, reports.

According to Zacks, “Kitov Pharmaceuticals Holdings Ltd. is a pharmaceutical company which focused on the development of therapeutic candidates. The company’s product candidate consists of KIT-302, is formulated for treatment of pain caused by osteoarthritis and hypertension, which can be pre-existing or caused by the treatment for OA. Kitov Pharmaceuticals Holdings Ltd. is based in Jerusalem, Israel. “

NASDAQ:KTOV opened at $1.13 on Tuesday. The company has a market cap of $17.33 million, a PE ratio of 2.90 and a beta of 4.42. KITOV PHARMA LT/S has a 52 week low of $0.56 and a 52 week high of $3.81.

A hedge fund recently raised its stake in KITOV PHARMA LT/S stock. Virtu Financial LLC increased its holdings in KITOV PHARMA LT/S (NASDAQ:KTOV) by 70.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,898 shares of the company’s stock after buying an additional 16,069 shares during the quarter. Virtu Financial LLC owned about 0.25% of KITOV PHARMA LT/S worth $47,000 at the end of the most recent reporting period. Institutional investors own 1.51% of the company’s stock.


Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.

Read More: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on KITOV PHARMA LT/S (KTOV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for KITOV PHARMA LT/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KITOV PHARMA LT/S and related companies with's FREE daily email newsletter.